VBI Vaccines Provides an Update on its Restructuring Proceedings

CAMBRIDGE, Mass. -- VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided an update on the restructuring proceedings announced on July 30, 2024. Read More

VBI Vaccines Provides an Update on its Restructuring Proceedings

VBI Vaccines Provides an Update on its Restructuring Proceedings

VBI Vaccines Provides an Update on its Restructuring Proceedings

VBI Vaccines Provides an Update on its Restructuring Proceedings

VBI Vaccines Provides an Update on its Restructuring Proceedings